CN117881692A - 用于神经元重编程的方法和组合物 - Google Patents
用于神经元重编程的方法和组合物 Download PDFInfo
- Publication number
- CN117881692A CN117881692A CN202280051836.7A CN202280051836A CN117881692A CN 117881692 A CN117881692 A CN 117881692A CN 202280051836 A CN202280051836 A CN 202280051836A CN 117881692 A CN117881692 A CN 117881692A
- Authority
- CN
- China
- Prior art keywords
- ascl1
- transcription factor
- mutant
- bhlh
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208627P | 2021-06-09 | 2021-06-09 | |
| US63/208,627 | 2021-06-09 | ||
| PCT/CA2022/050923 WO2022256933A1 (en) | 2021-06-09 | 2022-06-09 | Method and compositions for neuronal reprogramming |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117881692A true CN117881692A (zh) | 2024-04-12 |
Family
ID=84424544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280051836.7A Pending CN117881692A (zh) | 2021-06-09 | 2022-06-09 | 用于神经元重编程的方法和组合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250282837A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4352085A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024521401A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240032021A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117881692A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022288230A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025888A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3222129A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309190A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014769A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022256933A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021078588A1 (en) * | 2019-10-21 | 2021-04-29 | École Polytechnique Fédérale De Lausanne (Epfl) | Synthesis of branching morphologies |
| CN115670390B (zh) * | 2022-12-30 | 2023-04-07 | 广东工业大学 | 一种帕金森病轴向症状严重程度表征方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037527A1 (en) * | 2012-09-07 | 2014-03-13 | Cambridge Enterprise Limited | Maturation of mammalian cells by modulation of protein phosphorylation |
-
2022
- 2022-06-09 EP EP22819038.5A patent/EP4352085A4/en active Pending
- 2022-06-09 MX MX2023014769A patent/MX2023014769A/es unknown
- 2022-06-09 KR KR1020247000754A patent/KR20240032021A/ko active Pending
- 2022-06-09 US US18/568,747 patent/US20250282837A1/en active Pending
- 2022-06-09 AU AU2022288230A patent/AU2022288230A1/en active Pending
- 2022-06-09 CN CN202280051836.7A patent/CN117881692A/zh active Pending
- 2022-06-09 IL IL309190A patent/IL309190A/en unknown
- 2022-06-09 BR BR112023025888A patent/BR112023025888A2/pt not_active Application Discontinuation
- 2022-06-09 WO PCT/CA2022/050923 patent/WO2022256933A1/en not_active Ceased
- 2022-06-09 CA CA3222129A patent/CA3222129A1/en active Pending
- 2022-06-09 JP JP2023575711A patent/JP2024521401A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250282837A1 (en) | 2025-09-11 |
| EP4352085A4 (en) | 2025-07-23 |
| CA3222129A1 (en) | 2022-12-15 |
| MX2023014769A (es) | 2024-01-30 |
| JP2024521401A (ja) | 2024-05-31 |
| EP4352085A1 (en) | 2024-04-17 |
| BR112023025888A2 (pt) | 2024-02-27 |
| KR20240032021A (ko) | 2024-03-08 |
| AU2022288230A1 (en) | 2023-12-21 |
| WO2022256933A1 (en) | 2022-12-15 |
| IL309190A (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230203531A1 (en) | Tissue selective transgene expression | |
| Volpicelli‐Daley et al. | How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease? | |
| Burton et al. | Gene therapy progress and prospects: Parkinson's disease | |
| Judson et al. | Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice | |
| JP2010531638A5 (cg-RX-API-DMAC7.html) | ||
| JP2013081480A (ja) | 標的化された細胞死 | |
| CN113728230B (zh) | 检测、预防、逆转和治疗神经系统疾病的方法 | |
| KR102599982B1 (ko) | 이식용 세포 집단 및 그의 제조 방법 | |
| KR20210133227A (ko) | 뉴런 세포 흥분성을 정상화하고 드라베 증후군을 치료하기 위한 개재뉴런-특이적 치료제 | |
| US20140243393A1 (en) | Methods of diagnosing and treating motor neuron diseases | |
| Shi et al. | Notch–Rbpj signaling is required for the development of noradrenergic neurons in the mouse locus coeruleus | |
| WO2017201425A1 (en) | Anabolic enhancers for ameliorating neurodegeneration | |
| US20250282837A1 (en) | Method and compositions for neuronal reprogramming | |
| Liu et al. | Deletion of Calsyntenin-3, an atypical cadherin, suppresses inhibitory synapses but increases excitatory parallel-fiber synapses in cerebellum | |
| Knorr et al. | The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor | |
| JP2005514403A (ja) | 運動ニューロンに対する標的化逆行性遺伝子送達 | |
| KR20220024104A (ko) | 파킨슨병을 위한 자가 세포 대체 요법 | |
| Hao et al. | Identification of a transient Sox5 expressing progenitor population in the neonatal ventral forebrain by a novel cis-regulatory element | |
| Cai et al. | Patch and matrix striatonigral neurons differentially regulate locomotion | |
| US20220042037A9 (en) | Adult Stem Cell Line Introduced with Hepatocyte Growth Factor Gene and Neurogenic Transcription Factor Gene with Basic Helix-Loop-Helix Motif and Uses Thereof | |
| Park | Developing a Direct Neuronal Reprogramming Strategy to Improve Motor Function in Amyotrophic Lateral Sclerosis | |
| Autar et al. | ASNTR Abstracts 2019 | |
| Pagliari | Optimization of AAV9 gene therapy for Spinal Muscular Atrophy with Respiratory Distress type 1 using in vivo disease models | |
| KR20250057176A (ko) | Arid4b 유전자 발현을 통한 신경세포로의 직접교차분화 유도 방법 | |
| TWI413690B (zh) | 具有泛素陽性包涵體之額顳葉退化症(ftld-u)之非人類動物模式 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |